242 related articles for article (PubMed ID: 36091227)
1. Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis
Li H; Xi Y; Liu H; Xin X
Front Nutr; 2022; 9():914079. PubMed ID: 36091227
[TBL] [Abstract][Full Text] [Related]
2. Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis.
Li H; Xi Y; Xin X; Tian H; Hu Y
Nutr Metab (Lond); 2020; 17():34. PubMed ID: 32377219
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice.
Li WC; Zhao SX; Ren WG; Zhang YG; Wang RQ; Kong LB; Zhang QS; Nan YM
Exp Ther Med; 2021 Aug; 22(2):830. PubMed ID: 34149876
[TBL] [Abstract][Full Text] [Related]
4. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
[TBL] [Abstract][Full Text] [Related]
5. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor.
Liu M; Zhang G; Wu S; Song M; Wang J; Cai W; Mi S; Liu C
J Ethnopharmacol; 2020 Jun; 255():112776. PubMed ID: 32205261
[TBL] [Abstract][Full Text] [Related]
6. Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis.
Li H; Xi Y; Xin X; Tian H; Hu Y
Biomed Pharmacother; 2020 Apr; 124():109915. PubMed ID: 31986416
[TBL] [Abstract][Full Text] [Related]
7. FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH.
Di Pasqua LG; Cagna M; Palladini G; Croce AC; Cadamuro M; Fabris L; Perlini S; Adorini L; Ferrigno A; Vairetti M
Liver Int; 2024 Jan; 44(1):214-227. PubMed ID: 37904642
[TBL] [Abstract][Full Text] [Related]
8. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
9. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
10. Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis
Li H; Xi Y; Xin X; Feng Q; Hu Y
Front Pharmacol; 2023; 14():1148737. PubMed ID: 37077819
[No Abstract] [Full Text] [Related]
11. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation.
Li H; Ying H; Hu A; Hu Y; Li D
Biol Pharm Bull; 2017; 40(5):650-657. PubMed ID: 28458350
[TBL] [Abstract][Full Text] [Related]
13. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
[TBL] [Abstract][Full Text] [Related]
14. Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXRα/FASN Signaling.
Xie Y; Shen F; He Y; Guo C; Yang R; Cao H; Pan Q; Fan J
Nutrients; 2023 Mar; 15(5):. PubMed ID: 36904254
[TBL] [Abstract][Full Text] [Related]
15. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
17. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
19. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease.
Gai Z; Gui T; Alecu I; Lone MA; Hornemann T; Chen Q; Visentin M; Hiller C; Hausler S; Kullak-Ublick GA
Liver Int; 2020 Apr; 40(4):844-859. PubMed ID: 31883408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]